Company Filing History:
2 out of 41 
2 out of 61 
Years Active: 2009-2010
Title: John Stingl: Innovator in Mammary Stem Cell Research
Introduction
John Stingl is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of mammary stem cell research, holding 2 patents that focus on innovative methods for isolating and discriminating mammary epithelial stem and colony-forming cells.
Latest Patents
Stingl's latest patents include a method for the discrimination and isolation of mammary epithelial stem and colony-forming cells. This invention relates to an improved method that allows for the differential isolation of mouse mammary stem cells and colony-forming cells (CFCs). The method involves the depletion of non-epithelial cells from freshly dissociated mouse mammary tissue by using an antibody composition containing antibodies specific for CD45, Ter119, CD35, and optionally CD140a. After forming conjugates between the non-epithelial mammary cells and the antibodies, the cell conjugates are removed. The remaining epithelial cells are then incubated with an antibody composition containing antibodies specific for CD24 and CD49f or CD24 and CD14. This process enables the differential isolation of mouse mammary stem and luminal-restricted CFC cells. Additionally, the invention includes kits for carrying out this method and the cell preparations produced by it.
Career Highlights
Throughout his career, John Stingl has worked with notable organizations such as Stemcell Technologies Inc. and the British Columbia Cancer Agency Branch. His work has significantly advanced the understanding of mammary stem cells and their applications in cancer research.
Collaborations
One of his key collaborators is Connie J Eaves, with whom he has worked closely in the field of stem cell research.
Conclusion
John Stingl's innovative methods and contributions to mammary stem cell research have established him as a leading figure in the field. His patents reflect a commitment to advancing scientific knowledge and improving methodologies in stem cell isolation.